Seres Therapeutics, Inc.

Clinical-stage biotech developing oral live bacterial therapeutics for serious diseases

What Seres Therapeutics does

Seres Therapeutics is developing medicines made from live, beneficial bacteria that are taken by mouth to restore a healthy gut microbiome. Its drug candidates aim to clear harmful germs from the gut, strengthen the gut lining, and calm the immune response to prevent dangerous infections. Its lead program targets bloodstream infections in patients who get stem cell transplants from a donor.

How Seres Therapeutics makes money

As a clinical-stage company, Seres has no approved products to sell and funds its research and development through capital raised from investors and partners. Any future revenue would depend on its candidates winning regulatory approval and being sold or licensed.

Products & services

• SER-155 (oral live biotherapeutic for allogeneic stem cell transplant patients)
• SER-603 (live biotherapeutic for GI microbiome disruption and mucosal barrier integrity)
• SER-147 (live biotherapeutic for infection prevention in chronic liver disease)